Abstract
The benefits of treating isolated systolic hypertension (ISH) have been established, but the most appropriate choice of drug is still uncertain. For this reason, a sustained-release formulation of isradipine was compared with spirapril in a double-blind randomized study in elderly Chinese patients with ISH. The dosage was titrated if necessary after 4 weeks of treatment. The reduction in systolic/diastolic blood pressure after 8 weeks was similar for both treatments--20/10 mm Hg with isradipine versus 24/6 mm Hg with spirapril--measured in the supine position. There were no orthostatic symptoms and both treatments were well tolerated.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Blood Pressure / drug effects
-
Delayed-Action Preparations
-
Double-Blind Method
-
Enalapril / adverse effects
-
Enalapril / analogs & derivatives*
-
Enalapril / therapeutic use
-
Female
-
Heart Rate / drug effects
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Isradipine / adverse effects
-
Isradipine / therapeutic use*
-
Male
-
Peak Expiratory Flow Rate / drug effects
-
Systole
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Delayed-Action Preparations
-
Enalapril
-
spirapril
-
Isradipine